)
Total IgE
concentrations
showed a progressive
decline
with DUPIXENT
treatment through
Week 522
Clinical utility of total serum IgE % change in AFRS has not been established. Definitive conclusions cannot be made.
Analysis in the safety population: At Week 52 (secondary endpoint), 67.10% reduction in total serum IgE from a baseline level of 1551.32 IU/mL with DUPIXENT (n=33) vs 12.23% increase from a baseline level of 1140.50 IU/mL with placebo (n=28).1
AFRS, allergic fungal rhinosinusitis; LSM, least squares mean.